Concentrations of metronidazole and tinidazole in female reproductive organs after a single intravenous infusion and after repeated oral administration

Männistö, Pekka T.; Karhunen, Markku; Mattila, J.; Koskela, Outi; Suikkari, Anne‐Maria; Heinonen, Pentti K.; Tuimala, Risto; Haataja, H.

doi:10.1007/bf01640899

Cited by 23 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparative studies of the tissue penetration of nitroimidazoles are scanty. These studies have, however, demonstrated that after the same dosage, the steady-state concentrations of tinidazole both in serum and in several tissues were remarkably high as compared with those of metronidazole (6,(8)(9)(10)(11). The same was the case in the present study concerning male genital tissues.…”

Section: Discussionsupporting

confidence: 60%

“…This difference is naturally caused by the long elimination half-life of tinidazole. As we have recommended previously (6,11), the dose interval of the tinidazole treatment could be prolonged to 12 h and the concentrations would still exceed those of metronidazole with equal dose. However, so far there are no clinical data supporting this proposal.…”

Section: Discussionmentioning

confidence: 99%

“…Metronidazole and tinidazole are known to penetrate well into various tissues after both enteral and parenteral administration (6,(8)(9)(10)(11). The elimination half-life of tinidazole is 12 to 15 h, and that of metronidazole is 7 to 9 h (8).…”

mentioning

confidence: 99%

“…The elimination half-life of tinidazole is 12 to 15 h, and that of metronidazole is 7 to 9 h (8). Owing to this difference, the steady-state concentrations of tinidazole in serum and tissues have been much higher than those given by the same dose of metronidazole (6,(8)(9)(10)(11). The prostate and the testis are problematic organs in regard to the tissue penetration of most drugs.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Concentrations of metronidazole and tinidazole in male genital tissues

Viitanen¹,

Haataja²,

Männistö³

1985

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The steady-state concentrations of metronidazole and tinidazole in male genital tissues were analyzed in patients subjected to elective gonadal surgery. The nitroimidazoles were administered orally at 500 mg every 8 h, beginning 5 days before the operation. Eight hours after the last dose, the concentrations of tinidazole were 24.1 +/- 2.5 micrograms (mean +/- standard error of the mean)/g of prostatic tissue, 29.1 +/- 2.9 micrograms/g of vas deferens, 22.1 +/- 2.1 micrograms/g of epididymis, and 18.6 +/- 2.3 micrograms/g of testis. The corresponding values of metronidazole were 14.3 +/- 1.8 micrograms/g, 15.9 +/- 1.2 micrograms/g, 14.0 +/- 1.2 micrograms/g, and 12.5 +/- 1.7 micrograms/g, respectively.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Concentrations of metronidazole and tinidazole in male genital tissues

Viitanen¹,

Haataja²,

Männistö³

1985

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Of these drugs, metronidazole and tinidazole are available in the United States and are cleared by the FDA for the oral or parenteral treatment of trichomoniasis. Tinidazole is generally more expensive, reaches higher levels in the serum and the genitourinary tract, has a longer half-life than metronidazole (12.5 hours versus 7.3 hours), and has fewer gastrointestinal side effects [662][663][664] . In randomized clinical trials, the recommended metronidazole regimens have resulted in cure rates of approximately 84-98% [665][666][667] , and the recommended tinidazole regimen has resulted in cure rates of approximately 92-100% 666,[668][669][670][671] .…”

Section: Alternative Regimenmentioning

confidence: 99%

1989 Sexually Transmitted Diseases Treatment Guidelines

&NA;

1990

The Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention. It does not represent and should not be construed to represent any agency determination or policy. Guidelines, 2010 (MMWR 201059 [No. RR-12] Contents IntroductionThe term sexually transmitted diseases (STDs)is used to refer to a variety of clinical syndromes and infections caused by pathogens that can be acquired and transmitted through sexual activity. Physicians and other health-care providers play a critical role in preventing and treating STDs. These guidelines for the treatment of STDs are intended to assist with that effort. Although these guidelines emphasize treatment, prevention strategies and diagnostic recommendations also are discussed.This document updates the CDC Sexually Transmitted Diseases Treatment Guidelines published in 2010 1 .These recommendations should be regarded as a source of clinical guidance and not prescriptive standards. Health-care providers should always consider the clinical circumstances of each person in the context of local disease prevalence. These guidelines are applicable to any patient-care setting that serves individuals at risk for STDs, including familyplanning clinics, HIV-care clinics, private physicians' offices, Federally Qualified Health Centers, and other primary-care facilities. These guidelines focus on the treatment and counseling of individuals and do not address other community services and interventions that are essential to STD/human immunodeficiency virus (HIV) prevention efforts. MethodsThese guidelines were developed by CDC staff and an independent workgroup selected on the basis of their expertise in the field of STDs. Members of the multidisciplinary workgroup included representation from federal, state, and local health departments, clinical and basic science researchers, and numerous professional organizations. (listed at the end of this document). All workgroup members provided conflict of interest form and several members of the workgroup acknowledged receiving financial support from companies performing clinical research All potential conflicts of interest were disclosed and managed in accordance with the editorial standards of the journals that published the scientific reports.Specifically in 2012, CDC staff and workgroup members were asked to identify key questions regarding STD treatment and clinical management that emerged since the 2010 STD Treatment Guidelines.Development of these key questions focused on four principal outcomes of STD therapy for each individual disease or infection: 1) treatment of infection based on microbiologic eradication; 2) alleviation of signs and symptoms; 3) prevention of sequelae; and 4) prevention of transmission, 5) cost-effectiveness and other advantages and disadvantages of specific regimens. Then, CDC staff members assigned workgroup members key questions to research, and with the ...

show abstract